This is to inform that due to some circumstances beyond the organizer control, “International Conference on Medicinal Chemistry, Computer Aided Drug Design and Delivery” (MCADD 2023) Hybrid event during September 14-16, 2023 at Valencia, Spain has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at medicinal-chemistry@magnusconference.com or call + 1 (702) 988 2320.
Drug discovery is a set of procedures that, when followed, result in the identification of drug molecules that are effective in treating or controlling disease targets. It all starts with a vast number of chemical compounds being screened to find the best disease targets. It necessitates knowledge of the drug receptor's structure so that drug molecules can be tailored to the binding site. Computer-aided drug design (CADD) is an ever-evolving scientific field with various elements. Computer-aided drug design (CADD) is a fascinating and diverse field in which applied and basic research collide and stimulate one another. Quantum mechanics and molecular modelling research such as structure-based drug design, ligand-based drug design, database searching, and binding affinity based on biological target information form the theoretical foundation of CADD. Any drug delivery system's purpose is to deliver a therapeutic amount of medicine to the appropriate spot in the body in order to establish and then maintain the correct drug concentration quickly. As a result, the drug delivery system should supply the drug at a rate determined by the body's needs during the treatment time.
Title : A qsar survey on tyrosine kinase inhibitors
Atefeh Hajiagha Bozorgi, Faculty of pharmacy, Iran (Islamic Republic of)
Title : Abbott diagnostics: COVID-19 inactivation, nucleocapsid antigen automated immunoassay development, and variant testing for automated and lateral flow assays binaxnow™ and panbio™
Philip M Hemken, Abbott Laboratories, United States
Title : Synthesis, antibacterial activity of 3-amino 5-methoxyl-2-methyl quinazolin-4(3H)-one an amino-6-methoxyl-2-methyl of 4H–benzo[d] [1,3]–oxazine–4–one
Osarumwense Peter Osarodion, Ondo State University of Sciences and Technology, Nigeria
Title : Tackling mycobacterium tuberculosis resistance with tailored isatin-pyrimidine hybrids enoyl acyl carrier protein reductase (Inha)
Amgad Albohy, The British University in Egypt (BUE), Egypt
Title : Transition metal complexes/Organometallic compounfs as anticancer drugs
Prakash kinthda, Nims university,jaipur,rajasthan, India
Title : New n-ribosides and n-mannosides of rhodanine derivatives with anticancer activity on leukaemia cell line: Design, synthesis, dft and molecular modelling studies
Ahmed, Kafrelsheikh University, Egypt